Clinical Trial Update: Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing esomeprazole magnesium 40 mg daily with lansoprazole 30 mg twice daily for symptom control in persistent gastroesophageal reflu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Esomeprazole magnesium (esomeprazole magnesium)
• Lansoprazole (Lansoprazole)

Snippet

Sponsor: AstraZeneca | Conditions: Heartburn, Gastroesophageal Reflux Disease | Phase 4 | Status: COMPLETED